TPST
Tempest Therapeutics, Inc.2.9100
-0.0300-1.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
14.34MP/E (TTM)
-Basic EPS (TTM)
-9.73Dividend Yield
0%Recent Filings
8-K
Tempest prices $4.25M offering
Tempest Therapeutics entered a securities purchase agreement on November 24, 2025, with one institutional investor for a registered direct offering of 487,000 common shares and prefunded warrants for 685,414 shares, plus concurrent private placement warrants for 1,172,414 shares at $3.625 per unit. Closing is set for November 26, yielding ~$4.25 million gross proceeds for working capital. Warrants are exercisable at $3.50 for 18 months post-resale registration. Dilution caps at 4.99% ownership.
8-K
Tempest buys CAR T assets, new CEO
Tempest signed an asset purchase agreement on November 19, 2025, to acquire four CAR T-cell therapies (ERI-2003, ERI-2206, ERI-3003, ERI-3206) from Erigen and Factor for 8,268,495 shares, diluting existing holders to 35% ownership. Matt Angel steps in as CEO and board member at closing, targeted for early 2026 pending stockholder approval, $5M pre-closing financing, and other conditions. New leadership grabs the wheel.
8-K
Q3 loss shrinks, cash burns
10-Q
Q3 FY2025 results
Tempest Therapeutics' Q3 10-Q filing for the period ended September 30, 2025, provides header details but no financial statements, revenue, profitability metrics, or y/y q/q deltas. Balance sheets, statements of operations, and cash flows are referenced in the index yet not included in the provided excerpt. Non-GAAP metrics not disclosed in the 10-Q. No M&A, debt, liquidity, or regulation details available. Cash position unknown. Clinical trial delays pose key risk.
8-K
Tempest gains China trial clearance
Tempest Therapeutics secured clearance in China to launch a pivotal trial of amezalpat combination therapy for first-line HCC, building on FDA and EMA approvals, while earning orphan drug designations from EMA for amezalpat in HCC and FDA for TPST-1495 in FAP. Cash dwindled to $14.3 million by June 30, 2025, from $30.3 million year-end, amid $7.9 million Q2 net loss—narrower than last year's $9.6 million—thanks to R&D cuts for strategic alternatives. Progress accelerates oncology pipeline. Yet risks loom in capital volatility.
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
INTS
Intensity Therapeutics, Inc.
0.44+0.02
JANX
Janux Therapeutics, Inc.
14.65-0.47
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
NBTX
Nanobiotix S.A.
22.32+0.18
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
TOVX
Theriva Biologics, Inc.
0.21+0.01